Chinese firm is granted licensing rights to BioLineRx's hep C drug

06/11/2013 | Pharmaceutical Business Review Online · Globes (Israel)

Jiangsu Chia-tai Tianqing Pharmaceutical secured exclusive rights to develop, produce and bring to market BioLineRx's BL-8030, an oral hepatitis C drug candidate, in China and Hong Kong. BioLineRx will keep the drug's development and commercialization rights in other parts of the world. The deal entitles BioLineRx to as much as $30 million in upfront and milestone fees plus sales royalties.

View Full Article in:

Pharmaceutical Business Review Online · Globes (Israel)

Published in Brief:

SmartBrief Job Listings for Health Care